Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, PfizerAccelerated Approval, Advanced Squamous Cell Cancer Of The Head & Neck (SCCHN), Business, Clinical Trials, Collaborations, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), PD-1/PD-L1 inhibitors, R&DCheckmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab. Read more September 5, 2018/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2018-09-05 07:00:472018-09-10 01:32:26Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer
